57 citations
,
July 2000 in “Toxicology Letters” K6/ODC transgenic mice are effective for quickly identifying cancer-causing chemicals.
November 2025 in “Journal of Investigative Dermatology”
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
A new compound from Royoporus badius activates immune cells and induces inflammatory responses.
January 2018 in “Journal of analytical, bioanalytical and separation techniques”
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
10 citations
,
October 2014 in “Journal of Ovarian Research” The IRS-2 Asp/Asp genotype may increase the risk of PCOS in Chinese women, especially if they are not obese.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
3 citations
,
November 2017 in “International Journal of Pharmacy and Pharmaceutical Sciences” January 2026 in “JCEM Case Reports” Genetics may play a significant role in gender dysphoria.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
June 2026 in “Journal of health economics and outcomes research” The study conducted a cost-per-responder analysis comparing ritlecitinib and baricitinib for treating severe alopecia areata. Ritlecitinib, a JAK3/TEC inhibitor, showed greater efficacy and a lower cost per responder than baricitinib, a JAK1/2 inhibitor, at both Weeks 24 and 52. Specifically, 52.10% of ritlecitinib initiators achieved a significant response by Week 24 compared to 36.28% for baricitinib. By Week 52, 40.26% of ritlecitinib users reached the desired outcome versus 30.63% for baricitinib. The cost per responder was lower for ritlecitinib at both time points, suggesting it may be a more cost-effective option for inclusion in treatment plans for severe alopecia areata.
37 citations
,
April 2018 in “Journal of Allergy and Clinical Immunology” A mutation in the IKZF1 gene causes immune system overactivity, linked to autoimmune diseases like lupus.
December 2012 in “http://isrctn.org/>” December 2023 in “International Journal of Dermatology” 37 citations
,
August 2011 in “Journal of Bone and Mineral Research” A girl had rickets due to a gene mutation affecting vitamin D response.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
September 1998 in “Hair transplant forum international” The document's content cannot be summarized because it is not accessible or understandable.
28 citations
,
August 2014 in “Journal of Assisted Reproduction and Genetics” The VEGF +405G allele may increase the risk of PCOS in South Indian women.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
September 2024 in “Journal of Medicine and Life” A specific gene mutation causes a severe skin disorder in a family.
2 citations
,
February 2022 in “Preprints.org” Fermented red ginseng marc may help treat atopic dermatitis by reducing inflammation and improving skin health.
September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
86 citations
,
November 2015 in “Journal of Gastroenterology” The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.
Suppressing ODC activity reduces tumor growth in hair follicles.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
February 1996 in “Clinical Pharmacology & Therapeutics” MK-386 reduces sebum DHT levels.